Endeavor BioMedicines Reports the First Patient Dosing Under P-IIb (WHISTLE-PF) Study of Taladegib (ENV-101) to Treat Idiopathic Pulmonary Fibrosis
Shots:
- Endeavor BioMedicines has dosed the first patient in its P-IIb (WHISTLE-PF) trial, evaluating taladegib (ENV-101), a Hedgehog pathway inhibitor, as a treatment for idiopathic pulmonary fibrosis (IPF). It also showed its effectiveness in its P-IIa study
- The P-IIb study assesses efficacy, safety & patient-reported outcomes of ENV-101 vs PBO as well as its effects on lung capacity and lung fibrosis, using HRCT imaging, in IPF patients across 14 countries incl. Australia for over 24wks.
- The P-IIa study results for ENV-101 demonstrated significantly improved lung function and total lung capacity as well as fibrosis reversal after 12wks. treatment, without any serious TRAEs or safety concerns
Ref: Endeavor BioMedicines | Image: Endeavor BioMedicines
Related News:- Pipeline Overview: Paul A. Frohna from Endeavor BioMedicines in Conversation with PharmaShots
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
